ASAudra J. Schwalk

Audra J. Schwalk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Audra J. Schwalk has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Abesh Niroula

    Emory University School of Medicine, Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Atlanta, Georgia, USA

    1 shared publication
  • Aitua C. Salami

    Dapartment of Cardiovascular and Thoracic Surgery, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

    1 shared publication
  • Anastasiia Rudkovskaia

    The University of Texas Southwestern Medical Center

    1 shared publication
  • Brandon Jakubowski

    Department of Medicine, Division of Pulmonary and Critical Care Medicine University of Texas Southwestern Medical Center, Dallas, TX

    1 shared publication
  • Carlos A. Jimenez

    Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    1 shared publication
  • David E. Ost

    Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Unit 1462, 1515 Holcombe Boulevard, Houston, TX 77030, USA

    1 shared publication

Latest Publications

  • Open Access

    Bronchoscopic Ablation and Intratumoral Therapies for Lung Cancer: Expanding Local Treatment Beyond Surgical Resection

    by Trevor Parton, Mayowa Oturko, Audra J. Schwalk, Aitua C. Salami, Laura Frye

    Advances in navigational bronchoscopy, robotic platforms, and intraprocedural imaging have transformed bronchoscopy from a diagnostic modality into a potential therapeutic platform for localized treatment of lung cancer. These developments are particularly relevant for patients who are medically inoperable, have limited pulmonary reserve, or require lung-sparing treatment strategies. This narrative review summarizes current evidence regarding bronchoscopic ablative technologies and intratumoral therapies for lung cancer. We discuss technological foundations including robotic bronchoscopy, electromagnetic and shape-sensing navigation, cone-beam computed tomography, augmented fluoroscopy, and radial endobronchial ultrasound. Available ablative modalities, including radiofrequency ablation, microwave ablation, cryoablation, photodynamic therapy, and pulsed electric field ablation, are reviewed alongside bronchoscopically delivered intratumoral chemotherapy, immunotherapy, and gene-based therapies. Early clinical studies demonstrate high technical success rates and favorable safety profiles for multiple bronchoscopic ablative approaches, with substantially lower rates of pleural complications compared with percutaneous techniques. Intratumoral therapies enable delivery of high local drug concentrations while minimizing systemic toxicity and may enhance antitumor immune responses through modulation of the tumor microenvironment. Emerging evidence suggests potential synergy between local ablation and immunotherapeutic strategies. However, available data remain limited by small sample sizes, heterogeneous treatment protocols, and a lack of randomized comparative studies. Bronchoscopic ablation and intratumoral therapies represent promising additions to the thoracic oncology armamentarium. Continued advances in navigation, imaging, and therapeutic delivery systems are enabling increasingly precise, minimally invasive interventions. Prospective clinical trials are needed to define optimal patient selection, procedural strategies, and integration with surgery, radiation, and systemic therapies within multidisciplinary lung cancer care.

  • Developing Interventions for Chronic Obstructive Pulmonary Disease

    by Audra J. Schwalk, Niral M. Patel, Nagendra Y. Madisi

    Chronic obstructive pulmonary disease (COPD) is an incurable, progressive respiratory disease that may have a significant negative impact on the morbidity and mortality of affected patients. A substantial portion of the world's population is affected by COPD, and despite optimal medical management with medications, supplemental oxygen, and pulmonary rehabilitation, many patients are left debilitated because of this disease. Bronchoscopic treatment modalities offer a less-invasive method for the treatment of refractory COPD compared to surgical interventions and have expanded the potential therapeutic options for these patients. Bronchoscopic lung volume reduction is aimed at decreasing the hyperinflation and air trapping that occur in emphysema, and the most studied and successful intervention is endobronchial valve placement. Endobronchial coils, polymeric sealants, and thermal ablation are other researched alternatives. Additional interventional procedures are being investigated for the treatment of the mucus hypersecretion and cough that are associated with the chronic bronchitis phenotype of COPD and include targeted lung denervation, metered dose spray cryotherapy, deobstruction balloon, and bronchial rheoplasty. This review summarizes the most recent evidence pertaining to available therapies for the management of COPD, including chronic bronchitis, with a particular focus on bronchoscopic interventions.


  • Complications of Palliative Interventions for Malignant Pleural Effusions

    by Audra J. Schwalk, Saadia A. Faiz, Carlos A. Jimenez

  • Open Access

    Overview of malignant central airway obstruction

    by Rachel E. Powers, Audra J. Schwalk

    Malignant central airway obstruction (MCAO) impacts many patients with advanced primary lung cancers and metastatic disease to the thorax and may cause substantial symptoms and functional limitations in those affected. Making the diagnosis may be challenging as symptoms are often non-specific but identification is improved with a heightened level of suspicion and newer thoracic imaging modalities. Bronchoscopy plays a crucial role in the diagnosis and management of MCAO and therapeutic interventions may be lifesaving and result in palliation of symptoms. This may ultimately improve a patient’s candidacy to receive additional systemic or local cancer therapies or potential tumor resection. After initial stabilization, it is important that patients with MCAO undergo prompt evaluation and treatment. Multiple bronchoscopic instruments are available for management depending on tumor characteristics, location of the obstruction, and viability of distal airways, and may be utilized in combination during therapeutic procedures. These modalities include dilation, endobronchial stent placement, thermal and non-thermal ablation, mechanical debulking, and novel endobronchial therapies. While these procedures are not without risk, there is ample evidence showing improvements in patient symptoms, quality of life, and survival following therapeutic bronchoscopy. This review article provides a general overview of the diagnosis and management of MCAO with a focus on bronchoscopic interventions.


  • What is new in mediastinal staging?

    by Audra J. Schwalk, Abesh Niroula, Matthew Schimmel

    Purpose of review: Appropriate staging is of utmost importance in nonsmall cell lung cancer (NSCLC), as the pathologic stage dictates both overall prognosis and appropriate therapeutic pathways. This article seeks to review the current recommendations for mediastinal staging of NSCLC and available modalities to achieve this. Landmark publications pertaining to recent advancements in NSCLC treatments are also highlighted and the role of specific bronchoscopic modalities for tissue acquisition are reviewed. Recent findings: Recent advancements in the treatment of NSCLC have made accurate mediastinal staging more important than ever. Guidelines and recommendations outlining patients that warrant invasive mediastinal staging are available and a systematic approach should be utilized when sampling is performed. Ensuring the adequacy of tissue for the growing number of molecular biomarkers that must be tested has been the focus of many recent studies. Summary: Appropriate mediastinal staging is crucial for the management of patients with NSCLC as is obtaining adequate tissue for diagnostic and therapeutic purposes. EBUS-TBNA is sufficient for the diagnosis of nonsmall cell and small cell lung carcinomas, but EBUS-guided intranodal forceps and cryobiopsy may provide more optimal specimen for patients with benign disease, such as sarcoidosis, or in cases of lymphoma. Further studies are necessary to better delineate the role of these techniques in the diagnosis and staging of mediastinal diseases before they become the primary diagnostic modalities.


  • Indwelling Pleural Catheters

    by Audra J. Schwalk, David E. Ost